Gabelli raises its rating on AngioDynamics ANGO to Hold as the company announces accretive deal to acquire Navilyst Medical for $372 million in cash and stock.
Gabelli comments, "Overall we think this is a strategic and accretive deal for ANGO. This deal also more than offsets the loss of the LC Bead distribution agreement and does not preclude the company from future tuck-ins to improve the product line. We are upgrading our recommendation to a HOLD now that we are gaining additional visibility into the company's future."
ANGO closed at $12.96 a share on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in